Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells

被引:77
作者
Catalano, A
Rodilossi, S
Rippo, MR
Caprari, P
Procopio, A
机构
[1] Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60131 Ancona, Italy
[2] Italian Natl Res Ctr Aging, Lab Cytol, I-60124 Ancona, Italy
[3] NCI, Neural Dev Grp, Mouse Canc Genet Program, NIH, Frederick, MD 21701 USA
关键词
D O I
10.1074/jbc.M406696200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant mesothelioma (MM) is strongly resistant to conventional chemotherapy by unclear mechanisms. We and others have previously reported that cytokine- and growth factor-mediated signal transduction is involved in the growth and progression of MM. Here, we identified a pathway that involves stem cell factor (SCF)/c-Kit/Slug in mediating multidrug resistance of MM cells. When we compared gene expression profiles between five MM cells and their multidrug-resistant (MM DX) sublines, we found that MM DX cells expressed both SCF and c-Kit and had higher mRNA levels of Slug. Knockdown of c-Kit or Slug expression with their respective small interfering RNA sensitized MM DX cells to the induction of apoptosis by different chemotherapeutic agents, including doxorubicin, paclitaxel, and vincristine. Transfection of c-Kit in parental MM cells in the presence of SCF up-regulated Slug and increased resistance to the chemotherapeutic agents. Moreover, MM cells expressing Slug showed a similar increased resistance to the chemotherapeutic agents. These results indicate that induction of Slug by autocrine production of SCF and c-Kit activation plays a key role in conferring a broad spectrum chemoresistance on MM cells and reveal a novel signal transduction pathway for pharmacological or genetic intervention of MM patients.
引用
收藏
页码:46706 / 46714
页数:9
相关论文
共 47 条
[1]   Hemopoietic growth factor receptor abnormalities in leukemia [J].
Alexander, WS ;
Nicola, NA .
LEUKEMIA RESEARCH, 1998, 22 (12) :1097-1111
[2]   Multidrug resistance - A multiplex phenomenon [J].
Baldini, N .
NATURE MEDICINE, 1997, 3 (04) :378-380
[3]   The pathogenesis of mesothelioma [J].
Carbone, M ;
Kratzke, RA ;
Testa, JR .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :2-17
[4]   Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments [J].
Catalano, A ;
Gianni, W ;
Procopio, A .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (02) :101-109
[5]   Reclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention [J].
Catalano, A ;
Graciotti, L ;
Rinaldi, L ;
Raffaelli, G ;
Rodilosso, S ;
Betta, P ;
Gianni, W ;
Amoroso, S ;
Procopio, A .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) :322-328
[6]   Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen [J].
Catalano, A ;
Romano, M ;
Martinotti, S ;
Procopio, A .
ONCOGENE, 2002, 21 (18) :2896-2900
[7]   Methionine aminopeptidase-2 regulates human mesothelioma cell survival - Role of bcl-2 expression and telomerase activity [J].
Catalano, A ;
Romano, M ;
Robuffo, I ;
Strizzi, L ;
Procopio, A .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) :721-731
[8]   Cell adhesion and signalling by cadherins and Ig-CAMs in cancer [J].
Cavallaro, U ;
Christofori, G .
NATURE REVIEWS CANCER, 2004, 4 (02) :118-132
[9]   STEEL FACTOR INFLUENCES THE DISTRIBUTION AND ACTIVITY OF MURINE HEMATOPOIETIC STEM-CELLS INVIVO [J].
FLEMING, WH ;
ALPERN, EJ ;
UCHIDA, N ;
IKUTA, K ;
WEISSMAN, IL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3760-3764
[10]   IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT [J].
FURITSU, T ;
TSUJIMURA, T ;
TONO, T ;
IKEDA, H ;
KITAYAMA, H ;
KOSHIMIZU, U ;
SUGAHARA, H ;
BUTTERFIELD, JH ;
ASHMAN, LK ;
KANAYAMA, Y ;
MATSUZAWA, Y ;
KITAMURA, Y ;
KANAKURA, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1736-1744